The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Weight Gain and Metabolic Risks Associated with Antipsychotic Medications in Children and Adolescents
Abstract
BACKGROUND: Antipsychotic-related weight gain and metabolic adverse effects have become a major focus, especially in youth. METHODS: Review of randomized, cohort, and pharmacoepidemiologic studies of antipsychotic-related weight gain and metabolic adverse effects and of interventions for their reduction in youth. RESULTS: Across 34 published head-to-head and placebo-controlled studies in youth with psychotic and bipolar disorders, weight gain ranged from 3.8 to 16.2 kg with olanzapine (n=353), 0.9-9.5 kg with clozapine (n=97), 1.9-7.2 kg with risperidone (n=571), 2.3-6.1 kg with quetiapine (n=133), and 0-4.4 kg with aripiprazole (n=451). In 24 placebo-controlled trials, the numbers-needed-to-harm for weight gain ≥7% in youth with bipolar disorder and schizophrenia were 39 (confidence interval [CI]: -1 to +6, not significant) for aripiprazole, 36 (CI: -1 to +7, not significant) for ziprasidone, 9 (CI: 7-14) for quetiapine, 6 (CI: 5-8) for risperidone, and 3 (CI: 3-4) for olanzapine. Data in youth with autism and disruptive behavior disorders, available only for some antipsychotics, suggest greater weight gain, possibly due to less prior antipsychotic exposure. Three-month results from a large cohort study in antipsychotic-naïve youth indicated that metabolic effects differ among second-generation antipsychotics, despite significant weight gain with all studied agents, suggesting additional, weight-independent effects. Further, pharmacoepidemiologic work indicates that antipsychotic polypharmacy increases the risk for obesity (odds ratio [OR]: 2.28 [CI: 1.49-3.65]) or any cardiovascular, cerebrovascular, or hypertensive adverse event (OR: 1.72 [CI: 1.10-2.69]). However, despite marked weight gain and its greater impact on youth, monitoring rates are low and studies of pharmacologic and behavioral interventions are extremely limited. CONCLUSIONS: More research is needed to develop strategies to minimize antipsychotic-related weight gain and metabolic effects in youth and to discover treatments with lower risk potential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Obesity and the Metabolic Syndrome in Children and Adolescents
Weiss, R., Dziura, J., Burgert, T. S., Tamborlane, W. V., Taksali, S. E., Yeckel, C. W., Allen, K., Lopes, M., Savoye, M., Morrison, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031049 · Cited by 3,459
Prevalence of High Body Mass Index in US Children and Adolescents, 2007-2008
Ogden, C. L. (2010) · JAMA · doi:10.1001/jama.2009.2012 · Cited by 3,200
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Second-Generation (Atypical) Antipsychotics and Metabolic Effects: A Comprehensive Literature Review
Newcomer, J. W. (2005) · CNS Drugs · doi:10.2165/00023210-200519001-00001 · Cited by 1,340
Increased incidence of non-insulin-dependent diabetes mellitus among adolescents
Pinhas-Hamiel, O., Dolan, L. M., Daniels, S. R., Standiford, D., Khoury, P. R., & Zeitler, P. (1996) · The Journal of Pediatrics · doi:10.1016/s0022-3476(96)80124-7 · Cited by 1,172
Kahn, R. S., Fleischhacker, W. W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I. P., Gheorghe, M. D., Rybakowski, J. K., Galderisi, S., Libiger, J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60486-9 · Cited by 1,088
Correll, C. U. (2009) · JAMA · doi:10.1001/jama.2009.1549 · Cited by 1,050
Self-citationDe Hert, M., Dekker, J. M., Wood, D., Kahl, K. G., Holt, R. I. G., & Möller, H.-J. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2009.01.005 · Cited by 951 · cited 1×
“…glucose and lipid abnormalities, and metabolic syndrome, particularly, of second-generation antipsychotics (SGAs), have become a clinical, research, and regulatory focus (Allison et al. 1999; American Diabetes Association et al. 2004; Lieberman et al. 2005; Kahn et al. 2008; De Hert et al. 2009).”
Davis, P. H., Dawson, J. D., Riley, W. A., & Lauer, R. M. (2001) · Circulation · doi:10.1161/hc4601.099486 · Cited by 884
Research works printed but not linked: 13
- Arman S, 2008, Saudi Med J, 29, 1130
- Chang KD, 2008, J Clin Psychiatry, 69, 4
- Colton CW, 2006, Prev Chronic Dis, 3, A42
- De Hert M, 2011, Nat Rev Endocrinol
- DelBello M, 2007, Presented at 46th Annual Meeting of the American College of Neuropsychopharmacology
- DelBello M, 2008, Presented at 63rd Annual Meeting of the Society of Biological Psychiatry
- Findling R, 2008, Presented at 55th Annual Meeting of the American Academy of Child and Adolescent Psychiatry
- Findling RL, 2010, J Am Acad Child Adolesc Psychiatry, 49, 583
- Findling RL, 2008, Presented at 55th Annual Meeting of the American Academy of Child and Adolescent Psychiatry
- Freeman-Fobbs P, 2003, J Natl Med Assoc, 95, 119
- Maayan L, 2010, Presented at New Clinical Drug Evaluation Unit 50th Anniversary Meeting
- McDougle CJ, 2008, J Clin Psychiatry, 69, 15
- 10.1034/j.1399-5448.2000.010106.x · doi:10.1034/j.1399-5448.2000.010106.x
Cited by
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347
Correll, C. U., Detraux, J., De Lepeleire, J., & De Hert, M. (2015) · World Psychiatry · doi:10.1002/wps.20204 · Cited by 820
Self-citationDevelopmental timing and critical windows for the treatment of psychiatric disorders
Marín, O. (2016) · Nature Medicine · doi:10.1038/nm.4225 · Cited by 374
Mitchell, A. J., Vancampfort, D., De Herdt, A., Yu, W., & De Hert, M. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs082 · Cited by 327
Cooper, S. J., Reynolds, G. P., order):, W. E. C.-A. (. A., Barnes, T., England, E., Haddad, P., Heald, A., Holt, R., Lingford-Hughes, A., Osborn, D., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116645254 · Cited by 292
Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management
Manu, P., Dima, L., Shulman, M., Vancampfort, D., De Hert, M., & Correll, C. U. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12445 · Cited by 285
Self-citationAggression in autism spectrum disorder: presentation and treatment options
Fitzpatrick, S., Srivorakiat, L., Wink, L., Pedapati, E., & Erickson, C. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s84585 · Cited by 271
Comer, J. S., Chow, C., Chan, P. T., Cooper-Vince, C., & Wilson, L. A. S. (2013) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2012.10.001 · Cited by 269
Caemmerer, J., Correll, C. U., & Maayan, L. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.03.017 · Cited by 182
Tye, C., Runicles, A. K., Whitehouse, A. J. O., & Alvares, G. A. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00751 · Cited by 177
Viral infection, inflammation and schizophrenia
Kneeland, R. E., & Fatemi, S. H. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.02.001 · Cited by 152
Ghanizadeh, A., Sahraeizadeh, A., & Berk, M. (2014) · Child Psychiatry & Human Development · doi:10.1007/s10578-013-0390-x · Cited by 134
Cotton, S., Luberto, C. M., Sears, R. W., Strawn, J. R., Stahl, L., Wasson, R. S., Blom, T. J., & Delbello, M. P. (2016) · Early Intervention in Psychiatry · doi:10.1111/eip.12216 · Cited by 96
The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children
Libowitz, M. R., & Nurmi, E. L. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.623681 · Cited by 99
Intervention in the Context of Development: Pathways Toward New Treatments
Veenstra-VanderWeele, J., & Warren, Z. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.232 · Cited by 34
Metadata
- Authors
- Maayan, L., & Correll, C. U.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2011-12
- Volume
- 21
- Issue
- 6
- Pages
- 517-535
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2041413669
- Cited by
- 252
- References
- 106
- FWCI
- 13.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.liebertpub.com/nv/resources-tools/text-and-data-mining-policy/121/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.